个人简介

个人介绍

王行环，男，医学博士、二级教授、一级主任医师、博士生导师，入选国家中青年人才。现任武汉大学中南医院院长，科技部创新人才培养示范基地主任，武汉大学中南医院泌尿外科和循证与转化医学学科带头人，武汉大学泌尿外科研究所所长，武汉大学循证与转化医学中心主任，湖北省人类遗传资源保藏中心主任，肿瘤精准诊疗技术与转化医学湖北省工程研究中心主任等。兼任国务院学位委员会学科评议组成员，中国研究型医院学会泌尿外科学专业委员会主任委员、中国医师协会泌尿外科医师分会副会长、湖北省医学会泌尿外科分会主任委员等。主持国家研发计划项目4项，以第一或通信作者发表论文300余篇。获全国最美科技工作者、全国创新争先奖牌（负责人）、国家技术发明奖二等奖、国家卫生计生突出贡献中青年专家、湖北省医学领军人才（第一层次）、中国名医百强榜Top 10 Dr.、中国医师奖、吴阶平医药创新奖、荆楚好老师特别奖等奖励及荣誉。

教育经历

1981.09-1986.07 湖北医学院（现武汉大学医学部），医学学士

1986.09-1989.06 湖北医学院（现武汉大学医学部），外科学硕士

1993.09-1996.06 北京医科大学（现北京大学医学部），（泌尿）外科学博士

工作经历

1989.07-1993.08 湖北医学院附属第二医院泌尿外科，主治医师

1996.07-1998.12 广东省人民医院泌尿外科，副主任医师

1998.12-2008.03 广东省人民医院泌尿外科，主任、主任医师

2008.03-至 今 武汉大学中南医院泌尿外科、主任、主任医师、教授

2014.09-至 今 武汉大学循证与转化医学中心，主任

2014.12-至 今 湖北省腔镜泌尿外科医学临床研究中心，主任

2015.09-至 今 武汉大学中南医院/第二临床学院，院长

2018.05-至 今 湖北省人类遗传资源保藏中心，主任

2018.11-至 今 肿瘤精准诊疗技术与转化医学湖北省工程研究中心，主任

2019.12-至 今 武汉大学泌尿外科研究所，所长

2020.02-至 今 武汉雷神山医院，党委书记、院长

2020.06-至 今 科技部创新人才培养示范基地，主任

荣誉奖励

全国最美科技工作者，个人

全国创新争先奖牌，负责人

国家技术发明二等奖，第1完成人

湖北省科技进步一等奖，第1完成人

国家卫生计生突出贡献中青年专家，个人

中国医师奖，个人

国之名医•卓越建树，个人

吴阶平医药创新奖，个人

湖北最美科技工作者，个人

荆楚好老师特别奖，个人

社会服务

国务院学位委员会学科评议组，成员

中国医师协会泌尿外科医师分会，副会长

中国研究型医院学会泌尿外科学专业委员会，主任委员

湖北省医学会泌尿外科学分会，主任委员

《现代泌尿外科学杂志》，主编

科研领域

在临床医教研一线工作36年，为我国泌尿外科手术由开放向微创的转型升级发挥了引领作用。创建经尿道等离子前列腺切除手术体系，改变了国内外前列腺增生外科治疗的策略和模式；创新腹腔镜4种新术式，完善了国际指南；创建动态随访信息的临床膀胱癌活库（条件性重编程细胞、类器官、PDX动物模型），开展直面临床的膀胱癌分子遗传特异性研究。主持国家重点研发计划项目4项，以第一或通信作者在《中华医学杂志》、JAMA、Lancet、Signal Transduct Target Ther、Eur Urol、JUrol等杂志发表论文300余篇，其中SCI论文170余篇，研究成果被写入26部国际指南和2部英文经典教科书；主持制定国家卫生行业标准和指南11部，主编专著6部；获发明专利9项、转化获医疗器械14项。

入选国家级中青年人才、湖北省医学领军人才（第一层次），作为第1完成人获国家技术发明二等奖1项、湖北省科技进步一等奖1项，先后获湖北省最美科技工作者、吴阶平医药创新奖、全国创新争先奖牌、全国最美科技工作者等奖励及荣誉。

代表性论文

1. Liu W, Shen D, Ju L, Zhang R, Du W, Jin W, Xiong K, Wang G, Qian K, Zhang Y, Xiao Y*,Wang X*. MYBL2 promotes proliferation and metastasis of bladder cancer through transactivation of CDCA3. Oncogene, 2022, doi: 10.1038/s41388-022-02456-x.

2. Xiao Y, Ju L, Qian K, Jin W, Wang G, Zhao Y, Jiang W, Liu N, Wu K, Peng M, Cao R, Li S, Shi H, Gong Y, Zheng H, Liu T, Luo Y, Ma H, Chang L, Li G, Cao X, Tian Y, Xu Z, Yang Z, Shan L, Guo Z, Yao D, Zhou X, Chen X, Guo Z, Liu D, Xu S, Ji C, Yu F, Hong X, Luo J, Cao H, Zhang Y*,Wang X*. Non-invasive diagnosis and surveillance of bladder cancer with driver and passenger DNA methylation in a prospective cohort study. Clin Transl Med, 2022, 12(8): e1008.

3. Jin YH, Zeng XT, Liu TZ, Bai ZM, Dou ZL, Ding DG, Fan ZL, Han P, Huang YR, Huang X, Li M, Li XD, Li YN, Li XH, Liang CZ, Liu JM, Ma HS, Qi J, Shi JQ, Wang J, Wang DL, Wang ZP, Wang YY, Wang YB, Wei Q, Xia HB, Xing JC, Yan SY, Zhang XP, Zheng GY, Xing NZ*, He DL*,Wang XH*; Chinese Urological Doctor Association (CUDA), Urological Association of Chinese Research Hospital Association (CRHA-UA), Uro-Health Promotive Association of China International Exchange, Promotive Association for Medical, Health Care (CPAM-UHPA). Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition). Mil Med Res, 2022, 9(1): 44.

4. Zeng XT, Jin YH, Liu TZ, Chen FM, Ding DG, Fu M, Gu XQ, Han BM, Huang X, Hou Z, Hu WL, Kang XL, Li GH, Li JX, Li PJ, Liang CZ, Liu XH, Liu ZY, Liu CX, Liu JM, Luo GH, Luo Y, Qin WJ, Qiu JH, Qiu JX, Shang XJ, Shi BK, Sun F, Tian GX, Tian Y, Wang F, Wang F, Wang YH, Wang YJ, Wang ZP, Wang Z, Wei Q, Xiao MH, Xu WH, Yi FX, Zhu CY, Zhuang QY, Zhou LQ, Zou XF, Xing NZ*, He DL*,Wang XH*; Chinese Urological Doctor Association (CUDA); Urological Association of Chinese Research Hospital Association (CRHA-UA); Uro-Health Promotive Association of China International Exchange and Promotive Association for Medical and Health Care (CPAM-UHPA). Clinical practice guideline for transurethral plasmakinetic resection of prostate for benign prostatic hyperplasia (2021 Edition). Mil Med Res, 2022, 9(1): 14.

5. Xu H, Ju L*, Xiong Y, Yu M, Zhou F, Qian K, Wang G, Xiao Y,Wang X*. E3 ubiquitin ligase RNF126 affects bladder cancer progression through regulation of PTEN stability. Cell Death Dis, 2021, 12(3):239.

6. Xiong Y, Ju L, Yuan L, Chen L, Wang G, Xu H, Peng T, Luo Y, Xiao Y*,Wang X*. KNSTRN promotes tumorigenesis and gemcitabine resistance by activating AKT in bladder cancer. Oncogene, 2021, 40(9): 1595-1608.

7. Qian K, Wang G, Ju L, Liu J, Luo Y, Wang Y, Peng T, Chen F, Zhang Y*, Xiao Y*,Wang X*. A novel germline EGFR variant p.R831H causes predisposition to familial CDK12-mutant prostate cancer with tandem duplicator phenotype. Oncogene, 2020, 39(44): 6871-6878.

8. Xiong Y, Yuan L, Chen S, Xu H, Peng T, Ju L, Wang G, Xiao Y*,Wang X*. WFDC2 suppresses prostate cancer metastasis by modulating EGFR signaling inactivation. Cell Death Dis, 2020, 11(7): 537.

9. Xiao Y, Qian K, Luo Y, Chen S, Lu M, Wang G, Ju L,Wang X*. Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Renal Failure Patients: A Potential Covert Source of Infection. Eur Urol, 2020, 78(2): 298-299.

10. Wang Y, Ju L, Guo Z, Qian K, Chen H, Zhang Y, Xiao Y*,Wang X*. Pedigree analysis of a POLD1 germline mutation in urothelial carcinoma shows a close association between different mutation burdens and overall survival. Cell Mol Immunol, 2021, 18(3): 767-769.

11. Ge Q, Lu M, Ju L, Qian K, Wang G, Wu CL, Liu X, Xiao Y*,Wang X*. miR-4324-RACGAP1-STAT3-ESR1 feedback loop inhibits proliferation and metastasis of bladder cancer. Int J Cancer, 2019, 144(12): 3043-3055.

12. Lu M, Ge Q, Wang G, Luo Y, Wang X, Jiang W, Liu X, Wu CL, Xiao Y*,Wang X*. CIRBP is a novel oncogene in human bladder cancer inducing expression of HIF-1α. Cell Death Dis, 2018, 9(10): 1046.

13. Yang Z, Liu T,Wang X*. Comparison of thulium laser enucleation and plasmakinetic resection of the prostate in a randomized prospective trial with 5-year follow-up. Lasers Med Sci, 2016, 31(9): 1797-1802.

14. Huang JY, Li S, Yang ZH, Zeng XT,Wang XH*. Efficacy and Safety of Plasmakinetic Resection of the Prostate in Patients with a Prostate Gland Larger than 80 cc: 30-Month Follow-Up Results. J Endourol, 2015, 29(8): 925-8.

15. Li S, Liu TZ,Wang XH*, Zeng XT, Zeng G, Yang ZH, Weng H, Meng Z, Huang JY. Randomized controlled trial comparing retroperitoneal laparoscopic pyelolithotomy versus percutaneous nephrolithotomy for the treatment of large renal pelvic calculi: a pilot study. J Endourol, 2014, 28(8): 946-50.

16. Wang X*, Li S, Liu T, Guo Y, Yang Z. Laparoscopic pyelolithotomy compared to percutaneous nephrolithotomy as surgical management for large renal pelvic calculi: a meta-analysis. J Urol, 2013, 190(3): 888-93.

17. Yang Z,Wang X*, Liu T. Thulium laser enucleation versus plasmakinetic resection of the prostate: a randomized prospective trial with 18-month follow-up. Urology, 2013, 81(2): 396-400.

18. Huang X, Wang L,Wang XH*, Shi HB, Zhang XJ, Yu ZY. Bipolar transurethral resection of the prostate causes deeper coagulation depth and less bleeding than monopolar transurethral prostatectomy. Urology, 2012, 80(5): 1116-20.

19. Wang XH*, Pu XY, Wang HP, Hu LQ. Laparoscopic radical cystectomy with orthotopic gastric neobladder: technique and initial outcomes. J Cancer Res Clin Oncol, 2009, 135(2):197-202.

20. Qu L,Wang X*, Huang X, Zhang Y, Zeng X. Use of a novel ex-vivo model to compare the hemostatic properties of plasmakinetic resection, transurethral vaporization resection and conventional transurethral resection of the prostate. Urology, 2007, 70(5): 1034-8.

21. Huang X,Wang XH*, Qu LJ, Pu XY, Zeng X. Bipolar versus monopolar transurethral resection of prostate: pathologic study in canines. Urology, 2007, 70(1):180-4.

22. Zhu FC*, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Li JX, Yang BF, Wang L, Wang WJ, Wu SP, Wang Z, Wu XH, Xu JJ, Zhang Z, Jia SY, Wang BS, Hu Y, Liu JJ, Zhang J, Qian XA, Li Q, Pan HX, Jiang HD, Deng P, Gou JB, Wang XW,Wang XH*, Chen W*. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, 2020, 396(10249): 479-488.

23. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y,Wang X*, Peng Z*. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA, 2020, 323(11): 1061-1069.

24. Wu S, Huang J, Zhang Z, Wu J, Zhang J, Hu H, Zhu T, Zhang J, Luo L, Fan P, Wang B, Chen C, Chen Y, Song X, Wang Y, Si W, Sun T,Wang X*, Hou L*, Chen W*. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infect Dis, 2021, 21(12): 1654-1664.

25. Pan Y, Jiang X, Yang L, Chen L, Zeng X, Liu G, Tang Y, Qian C, Wang X, Cheng F, Lin J*,Wang X*, Li Y*. SARS-CoV-2-specific immune response in COVID-19 convalescent individuals. Signal Transduct Target Ther, 2021, 6(1):256.

26. Jin YH, Zhan QY, Peng ZY, Ren XQ, Yin XT, Cai L, Yuan YF, Yue JR, Zhang XC, Yang QW, Ji J, Xia J, Li YR, Zhou FX, Gao YD, Yu Z, Xu F, Tu ML, Tan LM, Yang M, Chen F, Zhang XJ, Zeng M, Zhu Y, Liu XC, Yang J, Zhao DC, Ding YF, Hou N, Wang FB, Chen H, Zhang YG, Li W, Chen W, Shi YX, Yang XZ, Wang XJ, Zhong YJ, Zhao MJ, Li BH, Ma LL, Zi H, Wang N, Wang YY, Yu SF, Li LY, Huang Q, Weng H, Ren XY, Luo LS, Fan MR, Huang D, Xue HY, Yu LX, Gao JP, Deng T, Zeng XT*, Li HJ*, Cheng ZS*, Yao X*,Wang XH*; Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM); Chinese Research Hospital Association (CRHA). Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version). Mil Med Res, 2020, 7(1):41.

27. Jin YH, Huang Q, Wang YY, Zeng XT, Luo LS, Pan ZY, Yuan YF, Chen ZM, Cheng ZS, Huang X, Wang N, Li BH, Zi H, Zhao MJ, Ma LL, Deng T, Wang Y,Wang XH*. Perceived infection transmission routes, infection control practices, psychosocial changes, and management of COVID-19 infected healthcare workers in a tertiary acute care hospital in Wuhan: a cross-sectional survey. Mil Med Res, 2020, 7(1): 24.

28. Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, Fang C, Huang D, Huang LQ, Huang Q, Han Y, Hu B, Hu F, Li BH, Li YR, Liang K, Lin LK, Luo LS, Ma J, Ma LL, Peng ZY, Pan YB, Pan ZY, Ren XQ, Sun HM, Wang Y, Wang YY, Weng H, Wei CJ, Wu DF, Xia J, Xiong Y, Xu HB, Yao XM, Yuan YF, Ye TS, Zhang XC, Zhang YW, Zhang YG, Zhang HM, Zhao Y, Zhao MJ, Zi H,Zeng XT*, Wang YY*, Wang XH*; for the Zhongnan Hospital of Wuhan University Novel Coronavirus Management and Research Team, Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM). A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res, 2020, 7(1):4.

实验室简介